EXCLUSIVE: Botanical Synthesis Tech-Focused BioHarvest's First Synthetic Olive Cells Shows Reduced Fat Accumulation in Liver Cells

On Tuesday, BioHarvest Sciences Inc. BHST published ‘in vitro' test results for its new olive cell compound, which can reduce fat accumulation in human liver cells.

BioHarvest demonstrated that its novel olive cell compound mitigated fat accumulation in human liver cells, both in a liver steatosis model and in experimental liver fibrosis models.

Also Read: EXCLUSIVE: BioHarvest Collaborates With Tate & Lyle To Develop Proprietary Plant-Based Molecules

The company attributes the reduction of fat accumulation in liver cells to the high levels of Verbascoside (a plant-derived polyphenol with known anti-inflammatory properties that has been researched for various effects on the liver) in BioHarvest's Olive cell compound.

Based on these results and additional studies to be conducted in 2025, the company expects to begin selling the Olive Cell product in 2026 as a nutraceutical product while continuing to explore the potential of partnering with a pharmaceutical company to provide the olive cell composition via a different regulatory path as part of its contract development and production organization (CDMO) model.

The Olive product will join VINIA as part of the company's portfolio. VINIA, a grape cell product that is high in Piceid Resveratrol, has been clinically shown to significantly dilate arteries, resulting in increased blood flow.

The company recently announced that VINIA had surpassed $50 million in sales, with over 50,000 active subscribers.

BioHarvest plans to support future growth by expanding its production capacity by 4x and building a new 100-ton-per-year production facility, which is expected to be operational in late 2026.

Price Action: BHST stock closed at $5.03 on Monday.

Read Next:

• Grocery Giant Albertsons Names Susan Morris As New CEO